Dr. Rappo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 1st Ave
New York, NY 10016Phone+1 212-686-7500
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Infectious Disease, 2009 - 2011
NYU Grossman School of MedicineResidency, Internal Medicine, 2006 - 2009
Drexel University College of MedicineClass of 2006
Certifications & Licensure
NY State Medical License 2009 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Start of enrollment: 2016 Mar 15
- Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis Start of enrollment: 2017 May 12
Publications & Presentations
PubMed
- 199 citationsTargeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation.Sara Federici, Sharon Kredo-Russo, Rafael Valdés-Mas, Denise Kviatcovsky, Eyal Weinstock
Cell. 2022-08-04 - 116 citationsDalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.Urania Rappo, Sailaja Puttagunta, Vadym Shevchenko, Alena Shevchenko, Alena Jandourek
Open Forum Infectious Diseases. 2019-01-01 - 14 citationsTreatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.Pedro L Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S McGregor, Sailaja Puttagunta
Drugs in Context. 2018-12-11
Press Mentions
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis ConferenceSeptember 18th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
